The global cannabidiol market was valued at USD 7.0 Billion in 2024 and is projected to reach USD 24.4 Billion by 2033, exhibiting a CAGR of 14.84% during 2025-2033. North America leads with a market share of over 40.4% driven by legalization, consumer awareness, and product innovations. The market is expanding due to rising chronic illnesses, regulatory approvals, and adoption of CBD products in wellness categories.
Study Assumption Years
Base Year: 2024
Historical Years: 2019-2024
Forecast Period: 2025-2033
Cannabidiol Market Key Takeaways
The global cannabidiol market size was USD 7.0 Billion in 2024.
The market is expected to grow at a CAGR of 14.84% during 2025-2033.
The forecast period spans from 2025 to 2033.
North America dominates with over 40.4% market share in 2024.
Increasing legalization and growing consumer awareness on health benefits are key growth drivers.
The U.S. Farm Bill supports hemp production, fostering distribution channels.
CBD’s adoption in pet wellness and strategic retail partnerships fuel growth.
Sample Request Link:
https://www.imarcgroup.com/cannabidiol-market/requestsample
Market Growth Factors
The primary driver propelling the cannabidiol market toward its USD 24.4 billion valuation is the ongoing wave of legalization and regulatory harmonization. As governments across North America and Europe dismantle legislative barriers, they create a transparent environment that encourages industrial investment and large-scale cultivation. The transition from restrictive laws to regulated frameworks—bolstered by milestones like the U.S. Farm Bill—has successfully reduced the social stigma surrounding hemp-derived products. Consequently, major pharmaceutical and consumer goods firms are now entering the space with greater confidence. This legislative support streamlines the global supply chain and ensures that products meet the standardized safety and quality benchmarks necessary for mainstream retail and widespread consumer adoption.
The intensifying global shift toward natural wellness and holistic health solutions is a critical factor sustaining the 14.84% CAGR. Modern consumers are increasingly seeking plant-based alternatives to manage lifestyle-related ailments such as chronic pain, anxiety, and sleep disorders. CBD’s non-psychoactive nature and therapeutic versatility make it a compelling choice for individuals wary of the side effects associated with traditional synthetic drugs. This demand is further amplified by a growing body of clinical research and rising awareness among healthcare professionals who now recommend CBD for its analgesic benefits. As mental health becomes a global priority, CBD’s role in stress management is positioning the compound as a fundamental component of the mainstream health and wellness industry.
Accelerated product innovation and the expansion of distribution channels are significantly expanding the market's reach into daily consumer life. Manufacturers are diversifying their portfolios far beyond traditional tinctures to include highly accessible formats such as functional beverages, edibles, and premium skincare topicals. This diversification appeals to broader demographics, including younger generations who view CBD as a lifestyle ingredient. Furthermore, the rise of e-commerce and specialized direct-to-consumer platforms has made high-quality CBD products accessible to a global audience, bypassing the logistical hurdles of traditional retail. By integrating CBD into everyday essentials like coffee and moisturizers, brands are successfully embedding the compound into the global consumer routine, ensuring consistent market growth through 2033.
Market Segmentation
Analysis by Product:
CBD Isolates: Dominant segment, offering 99% purity cannabidiol without other cannabinoids. Preferred in regions with strict THC limits, these are available as powders and crystals for diverse uses in edibles, cosmetics, and topicals.
Analysis by Source Type:
Marijuana: Leading with 58.1% market share in 2024, marijuana-based CBD benefits from higher THC levels enhancing the entourage effect. Availability in legal recreational and medical markets supports this demand.
Analysis by Grade:
Therapeutic Grade: Constitutes 62.7% market share in 2024, focused on medical and wellness applications targeting anxiety, chronic pain, and sleep disorders. Known for strict quality assurance, this grade is backed by clinical studies and medical endorsements.
Analysis by Sales Type:
B2B: Leading segment with 55.7% market share in 2024, driven by transactions between manufacturers and various businesses such as wholesalers and retailers. Bulk and recurring sales enhance market stability.
Regional Insights
North America dominates the cannabidiol market with over 40.4% share in 2024, owing to progressive legalization and regulatory frameworks enhancing consumer trust. The region benefits from established cannabis research infrastructure, fostering continual innovation. The United States alone accounts for 82.8% of North America’s market, supported by laws like the 2018 Farm Bill and rising adoption of CBD in healthcare, beauty, and wellness sectors. This strong market foundation is driving accelerated growth and expanding product availability.
Recent Developments & News
November 2024: The Cannabist Company partnered with Veda Warrior to launch cannabis-infused cooking essentials in New Jersey, aiming to widen access to cannabis wellness.
October 2024: Aurora Cannabis Inc., in collaboration with MedReleaf Australia, expanded its premium medical cannabis oil range in Australia.
January 2023: Medical Marijuana, Inc.’s subsidiary, HempMeds Brasil, introduced two new full-spectrum CBD products with concentrations of 3,000-6,000 mg in Brazil.
October 2022: High Tide Inc. launched NuLeaf Naturals multi-cannabinoid products in Ontario, Canada, including full spectrum hemp oils.
June 2021: The Valens Company acquired Green Roads for approximately USD 60 Million to expand its supply capabilities in the US and global markets.
Key Players
Aurora Cannabis Inc.
Canopy Growth Corporation
CV Sciences Inc.
Elixinol Global Limited
Endoca BV
Folium Biosciences
Green Roads of Florida LLC (The Valens Company Inc.)
Isodiol International Inc.
Koi CBD
Medical Marijuana Inc.
Medterra CBD
NuLeaf Naturals LLC
PharmaHemp d.o.o.
Tilray Brands Inc.
Get Custom Market Research Report for Your Business:
https://www.imarcgroup.com/request?type=report&id=12764&flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
